Zentalis Pharmaceuticals, Inc. 8-K

What Happened

• On March 26, 2026, Zentalis Pharmaceuticals, Inc. announced its financial results for the year ended December 31, 2025 and commented on certain business updates.
• The company furnished the full press release as Exhibit 99.1 to the Form 8-K; that press release is incorporated by reference into the filing.

Key Details

• Filing date: March 26, 2026 (Form 8-K, Item 2.02 Reporting of Results of Operations and Financial Condition).
• Reporting period: Year ended December 31, 2025.
• Disclosure format: Results and business updates were issued via a press release provided as Exhibit 99.1 to the 8-K.
• The 8-K supplies the press release text by reference rather than embedding extended financial statements in the body of the report.

Why It Matters

• This 8-K signals that Zentalis has released its annual earnings and related business commentary; those results (revenue, net loss/profit, cash position, or program progress) are contained in the press release and are material for evaluating the company’s financial health and near-term outlook.
• Retail investors should review Exhibit 99.1 (the press release) for the specific financial figures and management commentary to assess impacts on valuation, cash runway, and clinical or business milestones.